Midday Gainers /Losers
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 11:45AM CST
NICK: 14.80 (+0.20), JRJC: 5.81 (-0.11), OCN: 14.88 (-0.14), ZAZA: 3.20 (+0.70), VNDA: 14.69 (+1.11), EPAX: 2.46 (-0.08), FES: 1.19 (-0.01), NQ: 4.32 (-0.36), TECU: 3.59 (-0.14), VRML: 1.81 (+0.15), MYOS: 7.10 (+0.07), PME: 2.00 (+0.10), ESPR: 35.97 (-0.08), ALNY: 93.52 (+0.97), IDSA: 4.52 (-0.18), PRLS: 6.85 (+0.01), ACHN: 13.06 (+1.22), SKYS: 11.05 (-0.95), RCPT: 122.05 (+4.05), AGIO: 109.67 (+2.45)
Hypercholesterolemia - Pipeline Review, H2 2014
M2 - Fri Dec 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/5snkwx/hypercholesterolem) has announced the addition of the "Hypercholesterolemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Amgen - Eli Lilly and Company - Merck & Co - Pfizer - Santaris Pharma - SoluBest - Alnylam Pharmaceuticals - Regeneron Pharmaceuticals - CrystalGenomics - Catabasis Pharmaceuticals - Planet Biotechnology - Zhejiang Hisun Pharmaceutical - Esperion Therapeutics - Progenra - Serometrix - Hanmi Pharmaceuticals - AtheroNova. - Immune Response BioPharma - Agilvax - Michigan Life Therapeutics - LondonPharma - Dybly For more information visit http://www.researchandmarkets.com/research/5s...lesterolem
JNJ: 104.59 (+0.31), ESPR: 35.97 (-0.08), MRK: 57.46 (+0.25), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), REGN: 400.12 (+6.07)
CORRECTION - Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 7:05PM CST
In a release issued under the same headline earlier today by The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) the ticker and exchange for Esperion Therapeutics, Inc. should read (Nasdaq:ESPR) (sted Nasdaq:EXPR).
ESPR: 35.97 (-0.08), NDAQ: 48.74 (-0.40)
Can the Rally in Esperion Therapeutics (ESPR) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:21AM CST
Can the Rally in Esperion Therapeutics (ESPR) Shares Continue?
ESPR: 35.97 (-0.08)
Surging Earnings Estimates Signal Good News for Esperion Therapeutics (ESPR) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 7:50AM CST
Esperion Therapeutics is seeing solid activity on the earnings estimate revision and has decent short-term momentum. The stock has also started to move higher lately, adding 20.5% over the past four weeks.
ESPR: 35.97 (-0.08)
InsiderInsights.com Daily Round Up 11/19/14: CJES, MGPI, PSX, STAA
InsiderInsights - at Seeking Alpha - Thu Nov 20, 1:58AM CST
PSX: 72.10 (-0.46), CJES: 13.39 (-0.29), CPS: 58.76 (+0.60), BAH: 27.08 (-0.03), MRD: 18.64 (-0.53), MGPI: 16.53 (+0.28), GOOG: 528.77 (-1.82), MAS: 25.17 (-0.14), ESPR: 35.97 (-0.08), NOW: 69.69 (+0.12), LNKD: 231.83 (+0.34), SCTY: 56.76 (+0.92), STAA: 9.11 (-0.08), AINC: 89.50 (+2.50), FANG: 60.18 (-1.51), SFXE: 4.42 (+0.04), APD: 148.58 (unch), CSCO: 28.30 (+0.05), FOLD: 7.94 (+0.06)
Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 18, 3:00PM CST
Pop quiz: Which one of these drug companies released major positive clinical trial data yesterday? Company Intraday Increase Monday from Friday's Close Merck 1.4% Regeneron Pharmaceuticals 3.3% ...
ESPR: 35.97 (-0.08), MRK: 57.46 (+0.25), REGN: 400.12 (+6.07)
Can The Uptrend Continue for Esperion (ESPR)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 8:38AM CST
Can The Uptrend Continue for Esperion (ESPR)?
ESPR: 35.97 (-0.08)
Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 7:51AM CST
Esperion Therapeutics, Inc. (ESPR) was a big mover last session, as its shares rose over 6% on the day.
DRTX: 24.16 (+0.41), LCI: 42.29 (+1.79), ESPR: 35.97 (-0.08), BIOD: 1.36 (-0.04)
Esperion up on Merck trial results
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 12:20PM CST
ESPR: 35.97 (-0.08)
Esperion Therapeutics to Present at Stifel 2014 Healthcare Conference
Business Wire - Wed Nov 12, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that president and chief executive officer, Tim M. Mayleben, will present at the Stifel 2014 Healthcare Conference in New York City, N.Y. on Wednesday, November 19, 2014 at 11:30 a.m. Eastern Time.
ESPR: 35.97 (-0.08)
Esperion Therapeutics to Host and Webcast Live Investor Event
Business Wire - Tue Nov 11, 3:30PM CST
--Webcast on Monday, November 17, 2014 at 7:30 p.m. Central Time/8:30 p.m. Eastern Time
ESPR: 35.97 (-0.08)
Esperion Therapeutics' (ESPR) CEO Tim Mayleben on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:25PM CST
ESPR: 35.97 (-0.08)
Esperion Therapeutics beats by $0.04
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:27PM CST
ESPR: 35.97 (-0.08)
Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports Third Quarter 2014 Financial Results
Business Wire - Mon Nov 10, 3:05PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today provided ETC-1002 development program updates and financial results for the third quarter ended September 30, 2014.
ESPR: 35.97 (-0.08)
Esperion Therapeutics to Present at Credit Suisse Healthcare Conference
Business Wire - Wed Nov 05, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced that president and chief executive officer, Tim M. Mayleben, will present at the Credit Suisse Healthcare Conference in Phoenix, AZ on Tuesday, November 11, 2014 at 8:00 a.m. Mountain Time/10:00 a.m. Eastern Time.
ESPR: 35.97 (-0.08)
Esperion Therapeutics to Provide Third Quarter 2014 Results
Business Wire - Mon Nov 03, 3:30PM CST
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced it will host a conference call and webcast to report operational and financial results for the third quarter 2014. The webcast will take place on Monday, November 10, 2014 at 4:30 p.m. Eastern Time.
ESPR: 35.97 (-0.08)
InsiderInsights.com Daily Round Up 10/21/14: AGCO, ESPR, FMI, BKCC
InsiderInsights - at Seeking Alpha - Wed Oct 22, 9:56AM CDT
LDRH: 33.82 (-0.26), BKCC: 8.15 (unch), RDEN: 20.56 (-0.24), AGCO: 45.46 (-0.81), MLNK: 3.69 (-0.01), ATRA: 28.00 (+0.41), DHR: 86.79 (-0.27), SHLD: 32.56 (-0.37), GOOG: 528.77 (-1.82), HPQ: 40.54 (+0.18), ATNI: 67.50 (-0.20), PM: 83.15 (-0.15), ESPR: 35.97 (-0.08), FMI: 23.99 (-0.10), LNKD: 231.83 (+0.34), MAT: 30.22 (-0.16), SYK: 96.00 (-0.61), IPGP: 75.14 (+0.30)
Multiple Insiders of Esperion Therapeutics, Inc. (ESPR)-NasdaqGM bought Shares of ESPR
M2 - Wed Oct 22, 7:32AM CDT
Reported by InsiderCow.com at 2014-10-21 12:20:02 ET
ESPR: 35.97 (-0.08)
Esperion Therapeutics Announces Closing of Follow-On Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock
Business Wire - Tue Oct 21, 3:05PM CDT
Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the closing of its follow-on public offering of 4,887,500 shares of common stock, offered at a price to the public of $20.00 per share, which includes the exercise in full by the underwriters of their option to purchase 637,500 additional shares of common stock. This exercise brings the net proceeds in the offering to $91.6 million, after deducting underwriting discounts and commissions and expenses payable by Esperion. Esperion intends to use the net proceeds from the offering, as well as its other existing capital resources, to fund the continued development of ETC-1002 through completion of the anticipated Phase 3 development program, which will include several clinical studies; chemistry, manufacturing and controls (CMC) scale up and supplies development; regulatory compliance and the remainder for working capital and general corporate and administrative expenses.
ESPR: 35.97 (-0.08), JPM: 62.48 (unch)